Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan

AbstractBackgroundEnzalutamide is a novel, non-steroidal anti-androgen that has demonstrated excellent anti-tumor activity for both non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC) patients, and that is being rapidly introduced into clinical practice in Japan.ObjectiveWe retrospectively investigated the treatment efficacy, safety profile, and prognostic factors of enzalutamide over a relatively long observation period in Japanese patients with nmCRPC and mCRPC.Patients and methodsThe medical records of 184 consecutive Japanese patients with nmCRPC and mCRPC who started enzalutamide treatment in our institution between January 2012 and April 2018 were reviewed. Efficacy and safety profiles were assessed and statistically analyzed.ResultsAmong these 184 patients, 44 (23.9%) nmCRPC patients, 89 (48.4%) docetaxel-na ïve mCRPC patients, and 51 docetaxel-pretreated (27.7%) mCRPC patients underwent enzalutamide therapy. The median prostate-specific antigen progression-free survival (PSA-PFS) and overall survival (OS) periods for nmCRPC patients were 39.2 months and not reached; those for docetaxel-naïve mCRPC p atients were 16.5 months and 59.8 months; and those for docetaxel-pretreated mCRPC patients were 7.0 months and 30.4 months, respectively. Multivariate analysis identified performance status ≥ 2, PSA >  8.89 ng/mL (median value), hemoglobin   3.0, and 4...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Zarrabi A, Mark S PMID: 33032299 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Publication date: Available online 7 October 2020Source: European UrologyAuthor(s): Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, Thomas Van den Broeck, Marcus G. Cumberbatch, Maria De Santis, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen, Nikolaos Grivas, Jeremy Grummet, Ann M. Henry, Theodorus H. van der Kwast, Thomas B. Lam, Michael Lardas, Matthew Liew, Malcolm D. Mason, Lisa Moris, Daniela E. Oprea-Lager
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Zhao Y, Cheng X, Wang G, Liao Y, Qing C Abstract Linalool is an unsaturated terpene that can be found in several plants and exhibits various biological activities. The aim of the present study was to investigate the anticancer activity of linalool using the human prostate cancer 22Rv1 cell line. Flow cytometry was employed to study the effects of linalool on the induction of apoptosis, cell cycle progression, loss of mitochondrial membrane potential and cytochrome c release, whereas the effects of linalool on apoptosis-associated proteins were investigated by western blot analysis. An efficacy study was co...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Kathy Siggins and Lynda Everman are thrilled to share the welcome news that the US Postal Service has reinstated sales of the Alzheimer’s Disease Research Semipostal Stamp effective October 5, 2020. It is now available for purchase at most post offices and online at https://store.usps.com/store/product/buy-stamps/alzheimers-S_564204, and by phone at 1-800 STAMP-24. Before it was withdrawn in November 2019, over 8.2 million stamps were sold during its two-year run raising $1,061,777 for NIH-supported research to advance better treatments, prevention, and one day, a cure of Alzheimer’s and related dementias. The ...
Source: Minding Our Elders - Category: Geriatrics Authors: Source Type: blogs
AbstractLike other malignancies, prostate tumors are thought to contain cancer stem-like cells (CSCs) that are responsible for growth, metastasis, and therapy resistance. ΔNp63 (also called p40) is a regulator of normal prostate stem/progenitor cell activities and a marker of normal basal epithelial cells. The levels of ΔNp63 are reduced in prostate adenocarcinomas, although there is also evidence that ΔNp63 is involved in CSC regulation and drives metastasis to t he bone. We studied metastatic deposits of prostate cancers with isoform-specific ΔNp63 and TAp63 antibodies. We identified p63-positive ...
Source: Virchows Archiv - Category: Pathology Source Type: research
ConclusionsThe findings from the study provided practical guidance for future clinicians when implementing a prehabilitation program. Future study is required to evaluate the effectiveness of such a prehabilitation program in improving patient engagement and preparedness for prostate cancer treatment.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Authors: Zhang X, Pang P, Jiang M, Cao Q, Li H, Xu Y, Li Y, Chen X, Han J Abstract Prostate cancer (PCa) is one of the most commonly diagnosed cancers in males worldwide. lncRNAs (long noncoding RNAs) play a significant role in the occurrence and development of PCa. eRNAs (enhancer RNAs) and SE-lncRNAs (superenhancer lncRNAs) are important elements of lncRNAs, but the role of eRNAs and SE-lncRNAs in PCa remains largely unclear. In this work, we identified 681 eRNAs and 292 SE-lncRNAs that were expressed differentially in PCa using a microarray. We also found that eRNAs transcribed from active open chromatin had sig...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Condition:   Prostate Cancer Intervention:   Biological: Blood sample Sponsor:   University Hospital, Montpellier Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Docetaxel | Japan Health | Prostate Cancer | Statistics | Taxotere